Loading news...
Generic drugmakers face pricing pressure, but companies like TEVA, SDZNY and RDY are betting on complex generics and biosimilars to protect growth.
HYDERABAD, India--(BUSINESS WIRE)---- $RDY #Abatacept--Dr. Reddy's announces USFDA acceptance to review its Biologics License Application (BLA) for proposed interchangeable biosimilar, Abatacept.
Bessemer Group Inc. raised its holdings in shares of Dr. Reddy's Laboratories Ltd (NYSE: RDY) by 30.9% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,350,988 shares of the company's stock after buying an additional 318,621 shares during the
Dr. Reddy's Laboratories (NYSE: RDY) reported a "resilient performance" in its fiscal third quarter of FY26, with revenue growth and steady profitability despite what management described as product-specific headwinds, led by lower lenalidomide sales and continued pricing pressure in U.S. and European generics. On the company's earnings call, Chief Financial Officer M.V. Narasimham (MVN) said consolidated
RDY posts flat Q3 earnings, while revenues miss estimates as global generics growth lagged, pressured by weaker North America sales.
Dr. Reddy's Laboratories Limited (RDY) Q3 2026 Earnings Call Transcript
HYDERABAD, India & PRINCETON, N.J.--(BUSINESS WIRE)---- $RDY #Antihistamineeyedrop--Dr. Reddy's launched Olopatadine Hydrochloride Ophthalmic Solution USP 0.7% (OTC), a generic equivalent of Extra-Strength Pataday® Once Daily Relief.
Generic drugmakers face U.S. pricing pressure, but TEVA, SDZNY and RDY gain momentum through complex generics and biosimilars.
Dr. Reddy's receives exclusive rights to develop and commercialise Eftilagimod Alfa in all countries outside North America, Europe, Japan, and Greater China Under the terms, Immutep to receive upfront payment of USD 20 million (~AUD 30. 2 million) and is also eligible to receive potential regulatory development and commercial milestone payments of up to USD 349.
Fisher Asset Management LLC trimmed its position in shares of Dr. Reddy's Laboratories Ltd (NYSE: RDY) by 20.6% during the undefined quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 2,019,515 shares of the company's stock after selling 522,987 shares during the period.
American Century Companies Inc. boosted its holdings in Dr. Reddy's Laboratories Ltd (NYSE: RDY) by 14.5% in the undefined quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 1,047,518 shares of the company's stock after purchasing an additional 133,045 shares during the quarter. American Century
BANGALORE, India--(BUSINESS WIRE)-- #AurigeneOncology--Aurigene Oncology Limited Announces Encouraging Initial Data From 1st Two Cohorts of Phase 1 Study of AUR112.
Dr. Reddy's Laboratories (NYSE: RDY - Get Free Report) and Bausch Health Cos (NYSE: BHC - Get Free Report) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their valuation, risk, analyst recommendations, profitability, institutional ownership, dividends and earnings. Institutional and Insider Ownership 3.8% of
Dr. Reddy's Laboratories remains a compelling buy due to underappreciated growth in biosimilars and GLP-1 segments, despite near-term headwinds. RDY's Q2 FY26 results showed modest revenue growth, with North America lagging but Europe and emerging markets offsetting declines through acquisitions and new launches. Key growth drivers include upcoming biosimilar Abatacept and generic GLP-1 drugs, with launches expected to boost earnings beyond FY27 as Revlimid headwinds subside.
RDY posts a Q2 earnings and revenue beat as global generics drive growth, while new launches and biosimilar advances shape its pipeline.
Dr. Reddy's Laboratories Limited (NYSE:RDY ) Q2 2026 Earnings Call October 24, 2025 10:00 AM EDT Company Participants Richa Periwal - Head of Investor Relations and Analytics Mannam Venkatanarasimham - CFO & Member of the Management Council Erez Israeli - CEO & Member of the Management Council Conference Call Participants Neha Manpuria - BofA Securities, Research Division Damayanti Kerai - HSBC Global Investment Research Bino Pathiparampil - Elara Securities (India) Private Limited, Research Division Saion Mukherjee - Nomura Securities Co. Ltd., Research Division Madhav Marda - Fidelity Investments Kunal Dhamesha - Macquarie Research Tushar Manudhane - Motilal Oswal Securities Limited, Research Division Kunal Randeria - Axis Capital Limited, Research Division Vivek Agrawal - Citigroup Inc., Research Division Harith Mohammed - Spark Institutional Equities Private Limited, Research Division Sumit Gupta - Centrum Broking Limited, Research Division Presentation Operator Good day, and welcome our quarter 2 fiscal year 2026 [indiscernible] Limited.
While AI hype reigns on Wall Street, the healthcare sector is still far from the peaks it reached during the COVID-19 pandemic. And what's more important, many of the biotech stocks remain outside of Mr. Market's interest zone. Since the exclusivity of key blockbusters of 'giants', including Merck and Pfizer, expires in the next 4 years, there is an urgent need to continue rejuvenating their portfolios of drugs.